Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETT REVOLUTION Trial: Vorinostat in Rett Syndrome
NCT07150013Phase 1Recruiting
- Sponsor
- Unravel Biosciences
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind, single-arm trial of vorinostat in Rett syndrome (RTT), sponsored by Unravel Biosciences. Primary endpoints: Adverse Events at 20 weeks, Treatment Discontinuations at 20 weeks and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
vorinostat
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT07150013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150013.